Top Markets
Coin of the day
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Rang in aandelen #17592
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Aandeelprijs
$8.16
Laatst gesynchroniseerd: 2025-06-26
Marktkapitalisatie
$234.57M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Regulus Therapeutics Inc. (RGLS)

Categorie

Aandelsplitsingen voor Regulus Therapeutics Inc. (RGLS)
Het aandeel Regulus Therapeutics Inc. (symbool: RGLS) heeft in totaal 2 splitsingen ondergaan.
De meest recente splitsing vond plaats op Jun 29, 2022.
Eén aandeel RGLS dat vóór Oct 04, 2018 werd gekocht, staat nu gelijk aan 0.0083333333333333 aandelen RGLS.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
2022-06-29 1:10 x0.1 x0.0083333333333333
2018-10-04 1:12 x0.083333333333333 x0.083333333333333
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
Bedrijf Aantal aandelen splitsingen Cumulatieve vermenigvuldiging Land
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH